|
Name |
Citreoanthrasteroid A
|
Molecular Formula | C28H40O2 | |
IUPAC Name* |
(3R,3aR,8S,11bR)-3-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-8-hydroxy-3a,6-dimethyl-2,3,4,7,8,9,10,11b-octahydro-1H-cyclopenta[a]anthracen-5-one
|
|
SMILES |
CC1=C2C[C@H](CCC2=CC3=C1C(=O)C[C@]4([C@H]3CC[C@@H]4[C@H](C)/C=C/[C@H](C)C(C)C)C)O
|
|
InChI |
InChI=1S/C28H40O2/c1-16(2)17(3)7-8-18(4)24-11-12-25-23-13-20-9-10-21(29)14-22(20)19(5)27(23)26(30)15-28(24,25)6/h7-8,13,16-18,21,24-25,29H,9-12,14-15H2,1-6H3/b8-7+/t17-,18+,21-,24+,25-,28+/m0/s1
|
|
InChIKey |
JEBBAGYMMFYRSR-ONNGXECCSA-N
|
|
Synonyms |
Citreoanthrasteroid A; Citreoanthrasteroide A
|
|
CAS | NA | |
PubChem CID | 11750171 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 408.6 | ALogp: | 6.8 |
HBD: | 1 | HBA: | 2 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 37.3 | Aromatic Rings: | 4 |
Heavy Atoms: | 30 | QED Weighted: | 0.586 |
Caco-2 Permeability: | -4.772 | MDCK Permeability: | 0.00002130 |
Pgp-inhibitor: | 0.946 | Pgp-substrate: | 0.921 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.903 |
30% Bioavailability (F30%): | 0.935 |
Blood-Brain-Barrier Penetration (BBB): | 0.021 | Plasma Protein Binding (PPB): | 93.02% |
Volume Distribution (VD): | 1.294 | Fu: | 2.47% |
CYP1A2-inhibitor: | 0.105 | CYP1A2-substrate: | 0.855 |
CYP2C19-inhibitor: | 0.224 | CYP2C19-substrate: | 0.932 |
CYP2C9-inhibitor: | 0.38 | CYP2C9-substrate: | 0.39 |
CYP2D6-inhibitor: | 0.095 | CYP2D6-substrate: | 0.538 |
CYP3A4-inhibitor: | 0.621 | CYP3A4-substrate: | 0.849 |
Clearance (CL): | 2.4 | Half-life (T1/2): | 0.057 |
hERG Blockers: | 0.016 | Human Hepatotoxicity (H-HT): | 0.364 |
Drug-inuced Liver Injury (DILI): | 0.121 | AMES Toxicity: | 0.015 |
Rat Oral Acute Toxicity: | 0.887 | Maximum Recommended Daily Dose: | 0.983 |
Skin Sensitization: | 0.05 | Carcinogencity: | 0.005 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.027 |
Respiratory Toxicity: | 0.931 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC006033 | 0.547 | D06JPB | 0.500 | ||||
ENC005707 | 0.486 | D0G8OC | 0.486 | ||||
ENC004738 | 0.486 | D0G5CF | 0.451 | ||||
ENC001092 | 0.486 | D0N1TP | 0.344 | ||||
ENC002665 | 0.473 | D0K5WS | 0.333 | ||||
ENC003120 | 0.465 | D01QUS | 0.320 | ||||
ENC004906 | 0.465 | D08SVH | 0.312 | ||||
ENC006035 | 0.461 | D02ZGI | 0.302 | ||||
ENC003053 | 0.461 | D02VPX | 0.296 | ||||
ENC004864 | 0.461 | D0Y7LD | 0.289 |